All News
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
MedPage Today
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read Article
What to do about pre-clinical RA?
RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, and in particular, what to do regarding pre-clinical RA.
Read Article
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM
Links:
Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/T7CRLzhOMD https://t.co/nYPEw72zOJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush RheumNow ( View Tweet)
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Will be begin using sputum instead of blood serologies to detect RA?
- sputum seropositive CCP may be associated with development of clinical RA
- 4 fold higher risk if (induced) sputum CCP+
@RheumNow #RNL2023 https://t.co/Z85GDwIyl8
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
Sputum antibody predicts future development of RA
Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA)
Strongest association with CCP IgA
Supports pre-RA as mucosal disease
@RheumNow https://t.co/Js4JPZiLDB
Eric Dein ericdeinmd ( View Tweet)
Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive
By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Could MTX every other week dosing be an option in patients with stable disease..?
#RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Long live the GOAT Rx: MTX 🐐🐐
History of usage dating back to 1950
Use 1st-line
Optimize dose
Supplement folic acid
Split dose
Give SQ
Use in combination therapy
Dr Joel Kremer #RNL2023 @RheumNow https://t.co/CCBvQoNHXo
Eric Dein ericdeinmd ( View Tweet)
#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer @RheumNow #RNL2023 https://t.co/i0LZoQuK0w
Janet Pope Janetbirdope ( View Tweet)
How is a biosimilar approved?
Comparative effectiveness study for the reason that the medication was initial approved required, not for other indications
Jonathan Kay shows ex of ETN-ykro vs reference ETN in RA
Non-inferior in immunogenicity, safety, efficacy
@RheumNow #RNL2023 https://t.co/OOHie9Qr5t
Eric Dein ericdeinmd ( View Tweet)
Was amazed at the tons of biosimilar TNF options @_connectedcare uses in Australia... coming soon to the US!
Jonathan Kay #RNL2022 shows the lists of biosimilar
May be w/in batch-to-batch variability, unintended drift, or deliberate process changes (evolution)
@RheumNow https://t.co/sfVQspxbyr
Eric Dein ericdeinmd ( View Tweet)
Jonathan Kay on #RNL2023:
Biosimilar is well-researched with cost savings
These savings should benefit the patients
Incentives for physicians as well in form of decreased prior auth burdens
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
RBC MTX polyglutamate levels may be the “truth serum” for those pts stating they are taking their MTX but you question it. Dr. Kremer @RheumNow #RNL2023
Dr. Rachel Tate uptoTate ( View Tweet)
